Login to Your Account

Circassia drops allergy vaccine programs after failure in dust mite trial

By Nuala Moran
Staff Writer

Tuesday, April 18, 2017

LONDON – Circassia Pharmaceuticals plc is ditching the allergy vaccines technology around which it was founded after a phase IIb field study failed to find a significant effect vs. placebo in reducing symptoms of house dust mite allergy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription